CEVEC Pharmaceuticals GmbH (CEVEC) signed a license agreement with Biogen Inc. for the use of CEVEC’s ELEVECTA Technology for the manufacturing of adeno-associated virus (AAV) vectors for gene therapy applications.
 
Under the agreement, Biogen has a non-exclusive license for CEVEC’s ELEVECTA Technology with the rights to use the technology across its portfolio of gene therapy products. CEVEC is eligible for technology access and milestone fees, including clinical development and commercial milestones, as well as royalties on net sales of products. Further details were not disclosed.
 
“We are delighted to strengthen our collaboration with Biogen with this license agreement, enabling them to use the ELEVECTA Technology as a platform and to efficiently manufacture AAV vectors for their growing gene therapy portfolio,” said Dr. Nicole Faust, CEO of CEVEC. “Over the last several years we have seen a strong need across Pharma and Biotech companies to establish scalable and robust manufacturing technologies for AAV vectors. This agreement represents the next major step on our ELEVECTA® journey. Biogen has been a great collaboration partner and we look forward to continuing to support them with our innovative technologies.”